PT  - JOURNAL ARTICLE
AU  - Cheng, Yafang
AU  - Ma, Nan
AU  - Witt, Christian
AU  - Rapp, Steffen
AU  - Wild, Philipp
AU  - Andreae, Meinrat O.
AU  - Pöschl, Ulrich
AU  - Su, Hang
TI  - Distinct regimes of particle and virus abundance explain face mask efficacy for COVID-19
AID  - 10.1101/2020.09.10.20190348
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.10.20190348
4099  - http://medrxiv.org/content/early/2020/09/11/2020.09.10.20190348.short
4100  - http://medrxiv.org/content/early/2020/09/11/2020.09.10.20190348.full
AB  - Abstract Airborne transmission is an important transmission pathway for viruses, including SARS-CoV-2. Regions with a higher proportion of people wearing masks show better control of COVID-19, but the effectiveness of masks is still under debate due to their limited and variable efficiencies in removing respiratory particles. Here, we analyze experimental data and perform model calculations to show that this contrast can be explained by the different abundance regimes between particles and viruses. Upon short-term exposure, respiratory particles are usually in a particle-rich regime, but respiratory viruses are often in a virus-limited regime where the numbers of viruses inhaled by susceptible people are below or close to the infectious dose. This virus-limited regime ensures mask efficacy and synergy of multiple preventive measures in reducing the infection risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by the Max Planck Society (MPG). Y.C. thanks the Minerva Program of MPGAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or the supplementary materials.